STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Stoke Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$24.82+0.65 (+2.69%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.71 (−25.98%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Stoke Therapeutics, Inc. saw revenue fall 86.2% to $27.59M over the twelve months to Jun 30, 2026. Operating income fell 654.5% to -$223.38M, moving the operating margin from 20.2% to -809.7%. Free cash flow was -$180.68M, down 395.5% from a year earlier.
Revenue
$27.59M
-86.2% vs. a year earlier
Operating income
-$223.38M
-654.5% vs. a year earlier
Free cash flow
-$180.68M
-395.5% vs. a year earlier
EPS, diluted
-$3.41
-501.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.64B
- P/E ratio
- –
- Price to sales
- 59.39
- Price to book
- 4.74
- Dividend yield
- –
- Free cash flow yield
- -11.03%
Fundamentals
- Revenue
- $27.59M
- Net income
- -$207.90M
- EPS, diluted
- -$3.41
- Free cash flow
- -$180.68M
- Book value per share
- $5.23
- Diluted shares
- 66M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$27.59M-86.2% YoY
Operating income
-$223.38M-654.5% YoY
Net income
-$207.90M-496.1% YoY
EPS, diluted
-$3.41-501.2% YoY
Free cash flow
-$180.68M-395.5% YoY
Reported periodTrailing twelve months